{"nctId":"NCT00439244","briefTitle":"Efficacy Study of Zoledronic Acid and Teriparatide Combination Therapy in Women With Osteoporosis","startDateStruct":{"date":"2006-12"},"conditions":["Osteoporosis"],"count":412,"armGroups":[{"label":"Zoledronic acid plus teriparatide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Zoledronic acid","Drug: Teriparatide"]},{"label":"Zoledronic acid","type":"EXPERIMENTAL","interventionNames":["Drug: Zoledronic acid"]},{"label":"Placebo zoledronic acid plus teriparatide","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Placebo","Drug: Teriparatide"]}],"interventions":[{"name":"Zoledronic acid","otherNames":["Reclast, Aclasta"]},{"name":"Placebo","otherNames":[]},{"name":"Teriparatide","otherNames":["Forteo/Forsteo™"]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion criteria:\n\n* Postmenopausal (PMO) women between 45 and 89 years of age.\n* Bone mineral density T score of -2.5 or less at femoral neck, total hip or lumbar spine OR\n* Bone mineral density T score of -2.0 or less at femoral neck, total hip or lumbar spine with at least one documented osteoporotic vertebral fracture or a previously documented history of an osteoporotic clinical non-vertebral fracture not due to excessive trauma\n\nExclusion criteria:\n\n* Any prior use of strontium\n* Any past or active kidney disease or problems with kidney function\n* Prior treatment with any intravenous (i.v.) or oral bisphosphonate (such as but not limited to alendronate, risedronate and pamidronate) longer than 3 months consecutively. If bisphosphonate exposure is less than or equal to 3 months , a washout period of 1 year to randomization is required\n* Calcium levels in blood within the normal range\n* Normal liver function\n* Non-osteoporotic forms of metabolic bone disease such as and not limited to Paget's disease of bone, osteomalacia, osteogenesis imperfecta or multiple myeloma\n* Less than 3 evaluable lumbar (L1-L4) vertebrae for dual energy x-ray absorptiometry (DXA) measurement\n* Treatment with osteoporotic therapies such as raloxifene, calcitonin or Hormone Replacement Therapy within 3 months of randomization\n* Allergy or previous exposure to teriparatide\n\nOther protocol-defined inclusion/exclusion criteria may apply","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"45 Years","maximumAge":"89 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 52","description":"BMD measurements of the lumbar spine (L1-L4) by Dual X-ray absorptiometry (DXA) were performed on all patients at screening, and Weeks 13, 26, and 52 (or early termination). Every attempt was made to obtain the BMD measurements at the scheduled visit. If this was not possible, a BMD measurement ± 7 days from the scheduled visit was obtained. For the Final DXA at Week 52, the window was 10 - 15 days prior to the final study visit. BMD scans were acquired locally and all results sent to a central reader for evaluation.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"7.51","spread":"0.414"},{"groupId":"OG001","value":"4.37","spread":"0.401"},{"groupId":"OG002","value":"7.05","spread":"0.398"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Lumbar Spine Bone Mineral Density (BMD) at Week 13 and Week 26","description":"BMD measurements of the lumbar spine (L1-L4) by Dual X-ray absorptiometry (DXA) were performed on all patients at screening, and Weeks 13, 26, and 52 (or early termination). Every attempt was made to obtain the BMD measurements at the scheduled visit. If this was not possible, a BMD measurement ± 7 days from the scheduled visit was obtained. For the Final DXA at Week 52, the window was 10 - 15 days prior to the final study visit. BMD scans were acquired locally and all results sent to a central reader for evaluation.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"4.65","spread":"0.302"},{"groupId":"OG001","value":"2.97","spread":"0.297"},{"groupId":"OG002","value":"2.88","spread":"0.297"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"6.31","spread":"0.337"},{"groupId":"OG001","value":"3.87","spread":"0.333"},{"groupId":"OG002","value":"4.45","spread":"0.330"}]}]}]},{"type":"SECONDARY","title":"Percent Change From Baseline in Total Hip Bone Mineral Density (BMD) at Week 13, Week 26 and Week 52","description":"BMD measurements of the total hip by Dual X-ray absorptiometry (DXA) were performed on all patients at screening, and Weeks 13, 26, and 52 (or early termination). Every attempt was made to obtain the BMD measurements at the scheduled visit. If this was not possible, a BMD measurement ± 7 days from the scheduled visit was obtained. For the final DXA at Week 52, the window was 10 - 15 days prior to the final study visit. BMD scans were acquired locally and all results sent to a central reader for evaluation.","paramType":"LEAST_SQUARES_MEAN","dispersionType":"Standard Error","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"2.54","spread":"0.222"},{"groupId":"OG001","value":"1.53","spread":"0.216"},{"groupId":"OG002","value":"0.75","spread":"0.216"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.31","spread":"0.265"},{"groupId":"OG001","value":"1.73","spread":"0.262"},{"groupId":"OG002","value":"0.89","spread":"0.259"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.33","spread":"0.312"},{"groupId":"OG001","value":"2.16","spread":"0.303"},{"groupId":"OG002","value":"1.10","spread":"0.304"}]}]}]},{"type":"SECONDARY","title":"Bone Resorption and Formation Biochemical Markers : N-terminal Propeptide of Type I Collagen (P1NP)","description":"Specialized tests for markers of bone formation such as n-terminal propeptide of type I collagen (P1NP) were performed at Baseline, and Weeks 4, 8, 26, 39, and 52. The amount of serum P1NP was determined by the central laboratory.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"52.72","spread":"24.815"},{"groupId":"OG001","value":"53.64","spread":"29.233"},{"groupId":"OG002","value":"55.69","spread":"28.631"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"61.74","spread":"27.269"},{"groupId":"OG001","value":"39.57","spread":"20.532"},{"groupId":"OG002","value":"93.63","spread":"52.418"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"39.91","spread":"22.412"},{"groupId":"OG001","value":"21.68","spread":"13.827"},{"groupId":"OG002","value":"99.27","spread":"48.404"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"65.26","spread":"68.922"},{"groupId":"OG001","value":"18.32","spread":"15.255"},{"groupId":"OG002","value":"156.97","spread":"109.740"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"97.00","spread":"112.804"},{"groupId":"OG001","value":"20.69","spread":"13.326"},{"groupId":"OG002","value":"153.92","spread":"103.065"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"112.87","spread":"106.987"},{"groupId":"OG001","value":"23.49","spread":"16.137"},{"groupId":"OG002","value":"137.53","spread":"93.170"}]}]}]},{"type":"SECONDARY","title":"Bone Resorption and Formation Biochemical Markers : Beta C-terminal Telopeptides of Type I Collagen (β-CTx)","description":"Specialized tests for markers of bone formation such as β-CTx were performed at Baseline, and Weeks 4, 8, 26, 39, and 52. The amount of serum β-CTx was determined by the central laboratory.","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.45","spread":"0.191"},{"groupId":"OG001","value":"0.44","spread":"0.218"},{"groupId":"OG002","value":"0.46","spread":"0.222"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.05","spread":"0.048"},{"groupId":"OG001","value":"0.05","spread":"0.059"},{"groupId":"OG002","value":"0.45","spread":"0.259"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.09","spread":"0.109"},{"groupId":"OG001","value":"0.07","spread":"0.112"},{"groupId":"OG002","value":"0.60","spread":"0.320"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.43","spread":"0.419"},{"groupId":"OG001","value":"0.12","spread":"0.117"},{"groupId":"OG002","value":"0.90","spread":"0.537"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.57","spread":"0.525"},{"groupId":"OG001","value":"0.15","spread":"0.108"},{"groupId":"OG002","value":"0.89","spread":"0.503"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"0.64","spread":"0.476"},{"groupId":"OG001","value":"0.17","spread":"0.122"},{"groupId":"OG002","value":"0.83","spread":"0.393"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":20,"n":137},"commonTop":["Arthralgia","Headache","Back pain","Nasopharyngitis","Nausea"]}}}